NASDAQ: ROIVRoivant Sciences Ltd Stock
$11.92-0.08 (-0.67%)
Updated Sep 19, 2024
ROIV Price
$11.92
Fair Value Price
-$2.12
Market Cap
$8.82B
52 Week Low
$8.25
52 Week High
$13.24
P/E
2.03x
P/B
1.62x
P/S
49.13x
PEG
N/A
Dividend Yield
N/A
Revenue
$158.30M
Earnings
$4.74B
Gross Margin
90.3%
Operating Margin
3,037.49%
Profit Margin
2,991.8%
Debt to Equity
0.11
Operating Cash Flow
-$708M
Beta
0.83
Next Earnings
Nov 11, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ROIV Overview
Roivant Sciences Limited researches and develops medicines. It develops product candidates for the treatment of solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company's drug discovery capabilities include a computational physics-based platform for in silico drug design and machine learning-based models for protein degradation. Roivant was founded in 2014 and is headquartered in London, UK.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ROIV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ROIV ($11.92) is overvalued by 662.25% relative to our estimate of its Fair Value price of -$2.12 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ROIV ($11.92) is not significantly undervalued (662.25%) relative to our estimate of its Fair Value price of -$2.12 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ROIV is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
There are 30 more ROIV due diligence checks available for Premium users.
Be the first to know about important ROIV news, forecast changes, insider trades & much more!
ROIV News
Valuation
ROIV fair value
Fair Value of ROIV stock based on Discounted Cash Flow (DCF)
Price
$11.92
Fair Value
-$2.12
Undervalued by
662.25%
ROIV ($11.92) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ROIV ($11.92) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ROIV price to earnings (PE)
For valuing profitable companies with steady earnings
Company
2.03x
Industry
-135.85x
Market
25.52x
ROIV is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ROIV is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
ROIV price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.62x
Industry
6.51x
ROIV is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ROIV's financial health
Profit margin
Revenue
$55.1M
Net Income
$95.3M
Profit Margin
172.9%
ROIV's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ROIV's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$6.5B
Liabilities
$601.2M
Debt to equity
0.11
ROIV's short-term assets ($6.00B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ROIV's short-term assets ($6.00B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ROIV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$192.8M
Investing
-$965.0k
Financing
-$660.6M
ROIV's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ROIV vs Biotech Stocks
Roivant Sciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.